SA01d

SA01d is a clinical-stage pharmaceutical program developed by Kensana Health that utilizes the SyqeAir metered-dose inhaler to deliver standardized medical cannabis. The program is specifically designed to evaluate the safety and functional impact of inhaled cannabinoids on cognitive function and driving performance. By employing the SyqeAir device, which allows for the precise aerosolization of granular cannabis flos, SA01d aims to achieve predictable pharmacokinetic profiles and minimize the psychoactive impairment often associated with non-standardized cannabis use. This precision-dosing approach is intended to support the safe use of medical cannabis in patients who need to maintain high levels of functional capability in their daily lives. SA01d is currently in Phase 4 development, focusing on real-world safety outcomes and functional assessments.

Other names

SyqeAir